
Richard McCallum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5579525/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessment of gastric emptying using a low fat meal: establishment of international control values. American Journal of Gastroenterology, 2000, 95, 1456-1462.	0.4	611
2	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. American Journal of Gastroenterology, 2008, 103, 753-763.	0.4	588
3	Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology, 2003, 125, 421-428.	1.3	530
4	Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology, 2017, 112, 775-784.	0.4	525
5	Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Digestive Diseases and Sciences, 1998, 43, 2398-2404.	2.3	500
6	Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology, 1998, 114, 456-461.	1.3	406
7	Gastric emptying in patients with gastroesophageal reflux. Gastroenterology, 1981, 80, 285-291.	1.3	397
8	Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterology and Motility, 2006, 18, 263-283.	3.0	316
9	Metoclopramide: Pharmacology and Clinical Application. Annals of Internal Medicine, 1983, 98, 86.	3.9	309
10	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Journal of Nuclear Medicine Technology, 2008, 36, 44-54.	0.8	295
11	Clinical Features of Idiopathic Gastroparesis Vary With Sex, Body Mass, Symptom Onset, Delay in Gastric Emptying, and Gastroparesis Severity. Gastroenterology, 2011, 140, 101-115.e10.	1.3	281
12	Abnormal gastric myoelectrical activity and delayed gastric emptying in patients with symptoms suggestive of gastroparesis. Digestive Diseases and Sciences, 1996, 41, 1538-1545.	2.3	270
13	Domperidone: Review of Pharmacology and Clinical Applications in Gastroenterology. American Journal of Gastroenterology, 2007, 102, 2036-2045.	0.4	243
14	Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. Journal of Gastrointestinal Surgery, 2005, 9, 102-108.	1.7	219
15	Gastric Electrical Stimulation With Enterra Therapy Improves Symptoms From Diabetic Gastroparesis in a Prospective Study. Clinical Gastroenterology and Hepatology, 2010, 8, 947-954.e1.	4.4	186
16	Gastric pacing is a new surgical treatment for gastroparesis. American Journal of Surgery, 2001, 182, 676-681.	1.8	175
17	Treatment of Diabetic Gastroparesis by High-Frequency Gastric Electrical Stimulation. Diabetes Care, 2004, 27, 1071-1076.	8.6	174
18	Similarities and Differences Between Diabetic and Idiopathic Gastroparesis. Clinical Gastroenterology and Hepatology, 2011, 9, 1056-1064.	4.4	174

#	Article	IF	CITATIONS
19	Cyclic vomiting syndrome in adults. Neurogastroenterology and Motility, 2008, 20, 269-284.	3.0	172
20	Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterology and Motility, 2010, 22, 113-133.	3.0	171
21	The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. American Journal of Gastroenterology, 1993, 88, 203-7.	0.4	169
22	Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with parkinson's disease. Movement Disorders, 1997, 12, 952-957.	3.9	164
23	Clinicalâ€histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterology and Motility, 2012, 24, 531.	3.0	164
24	Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut, 2001, 49, 395-401.	12.1	150
25	Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis. JAMA - Journal of the American Medical Association, 2013, 310, 2640.	7.4	149
26	Dietary Intake and Nutritional Deficiencies in Patients With Diabetic or Idiopathic Gastroparesis. Gastroenterology, 2011, 141, 486-498.e7.	1.3	148
27	Gastric Electrical Stimulation Improves Outcomes of Patients With Gastroparesis for up to 10 Years. Clinical Gastroenterology and Hepatology, 2011, 9, 314-319.e1.	4.4	146
28	Functional Dyspepsia and Gastroparesis in Tertiary Care are Interchangeable Syndromes With Common Clinical and Pathologic Features. Gastroenterology, 2021, 160, 2006-2017.	1.3	141
29	Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Alimentary Pharmacology and Therapeutics, 1999, 13, 77-80.	3.7	132
30	Definition of a gastric emptying abnormality in patients with anorexia nervosa. Digestive Diseases and Sciences, 1985, 30, 713-722.	2.3	131
31	A Multicenter Placebo-controlled Clinical Trial of Oral Metoclopramide in Diabetic Gastroparesis. Diabetes Care, 1983, 6, 463-467.	8.6	130
32	Viral gastroparesis: a subgroup of idiopathic gastroparesisclinical characteristics and long-term outcomes. American Journal of Gastroenterology, 1997, 92, 1501-4.	0.4	126
33	Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. Clinical Therapeutics, 1998, 20, 438-453.	2.5	125
34	Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. Gastroenterology, 2017, 153, 1240-1250.e2.	1.3	125
35	Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. Gastroenterology, 2018, 154, 65-76.e11.	1.3	117
36	Dumping Syndrome: A Review of the Current Concepts of Pathophysiology, Diagnosis, and Treatment. Digestive Diseases and Sciences, 2016, 61, 11-18.	2.3	114

#	Article	IF	CITATIONS
37	Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clinical Gastroenterology and Hepatology, 2005, 3, 49-54.	4.4	113
38	Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis. Gastroenterology, 2016, 151, 87-96.e6.	1.3	112
39	Clinical Significance of Gastric Myoelectrical Dysrhythmias. Digestive Diseases, 1995, 13, 275-290.	1.9	110
40	Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis. Gastroenterology, 2015, 149, 1762-1774.e4.	1.3	110
41	Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis – a randomized, multicentre, placeboâ€controlled study. Alimentary Pharmacology and Therapeutics, 2007, 26, 1121-1130.	3.7	108
42	Gastric Myoelectrical Activity and Gastric Emptying in Patients With Functional Dyspepsia. American Journal of Gastroenterology, 1999, 94, 2384-2389.	0.4	107
43	Symptom responses, longâ€ŧerm outcomes and adverse events beyond 3 years of highâ€frequency gastric electrical stimulation for gastroparesis. Neurogastroenterology and Motility, 2006, 18, 18-27.	3.0	103
44	Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterology and Motility, 2013, 25, 427.	3.0	103
45	Mechanisms of symptomatic improvement after gastric electrical stimulation in gastroparetic patients. Neurogastroenterology and Motility, 2010, 22, 161-e51.	3.0	97
46	Effect of Metoclopramide in Diabetic Gastroparesis. Journal of Clinical Gastroenterology, 1985, 7, 25-32.	2.2	96
47	Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi enter, placebo ontrolled trial. Alimentary Pharmacology and Therapeutics, 2007, 26, 107-116.	3.7	96
48	Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. Neurogastroenterology and Motility, 2013, 25, 815.	3.0	95
49	Chronic Gastric Electrical Stimulation for Gastroparesis Reduces the Use of Prokinetic and/or Antiemetic Medications and the Need for Hospitalizations. Digestive Diseases and Sciences, 2005, 50, 1328-1334.	2.3	94
50	Phase 2b, randomized, doubleâ€blind 12â€week studies of <scp>TZP</scp> â€102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology and Motility, 2013, 25, e705-17.	3.0	94
51	Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. American Journal of Gastroenterology, 1993, 88, 485-90.	0.4	94
52	Association of the status of interstitial cells of Cajal and electrogastrogram parameters, gastric emptying and symptoms in patients with gastroparesis. Neurogastroenterology and Motility, 2010, 22, 56.	3.0	93
53	Further experience with gastric stimulation to treat drug refractory gastroparesis. American Journal of Surgery, 2003, 186, 690-695.	1.8	92
54	The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. American Journal of Gastroenterology, 1997, 92, 976-80.	0.4	89

#	Article	IF	CITATIONS
55	Treatment of gastroparesis with electrical stimulation. Digestive Diseases and Sciences, 2003, 48, 837-848.	2.3	87
56	Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology, 1983, 84, 1573-1577.	1.3	86
57	Effect of highâ€frequency gastric electrical stimulation on gastric myoelectric activity in gastroparetic patients. Neurogastroenterology and Motility, 2004, 16, 205-212.	3.0	84
58	Association of low numbers of <scp>CD</scp> 206â€positive cells with loss of <scp>ICC</scp> in the gastric body of patients with diabetic gastroparesis. Neurogastroenterology and Motility, 2014, 26, 1275-1284.	3.0	83
59	Delayed Gastric Emptying in Gastroesophageal Reflux Disease: Reassessment with New Methods and Symptomatic Correlations. American Journal of the Medical Sciences, 2004, 327, 1-4.	1.1	81
60	Diabetic and idiopathic gastroparesis is associated with loss of <scp>CD</scp> 206â€positive macrophages in the gastric antrum. Neurogastroenterology and Motility, 2017, 29, e13018.	3.0	77
61	Efficacy of Tricyclic Antidepressant Therapy in Adults With Cyclic Vomiting Syndrome. Journal of Clinical Gastroenterology, 2010, 44, 18-21.	2.2	74
62	Treatment of highâ€frequency gastric electrical stimulation for gastroparesis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1017-1026.	2.8	72
63	Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting - randomised clinical study subset data. Alimentary Pharmacology and Therapeutics, 2011, 33, 679-688.	3.7	69
64	Review article: cyclic vomiting syndrome in adults – rediscovering and redefining an old entity. Alimentary Pharmacology and Therapeutics, 2011, 34, 263-273.	3.7	69
65	The human jejunum has an endogenous microbiota that differs from those in the oral cavity and colon. BMC Microbiology, 2017, 17, 160.	3.3	66
66	Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterology and Motility, 2018, 30, e13196.	3.0	65
67	The rumination syndrome: clinical and manometric profile, therapy, and long-term outcome. Digestive Diseases and Sciences, 1997, 42, 1866-1872.	2.3	64
68	Dumping Syndrome: Establishing Criteria for Diagnosis and Identifying New Etiologies. Digestive Diseases and Sciences, 2010, 55, 117-123.	2.3	63
69	Association between changes in symptoms and gastric emptying in gastroparetic patients treated with gastric electrical stimulation. Neurogastroenterology and Motility, 2008, 20, 464-470.	3.0	61
70	Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterology and Motility, 2016, 28, 1902-1914.	3.0	61
71	The Long-Term Efficacy and Safety of Pyloroplasty Combined with Gastric Electrical Stimulation Therapy in Gastroparesis. Journal of Gastrointestinal Surgery, 2017, 21, 222-227.	1.7	60
72	Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in PatientsÂWith Gastroparesis. Clinical Gastroenterology and Hepatology, 2019, 17, 1285-1294.e1.	4.4	60

#	Article	IF	CITATIONS
73	Depleted interstitial cells of Cajal and fibrosis in the pylorus: Novel features of gastroparesis. Neurogastroenterology and Motility, 2016, 28, 1048-1054.	3.0	59
74	Spectrum of gastric emptying patterns in adult patients with cyclic vomiting syndrome. Neurogastroenterology and Motility, 2010, 22, 1298-e338.	3.0	57
75	Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterology and Motility, 2017, 29, e12981.	3.0	57
76	Effect of Domperidone, an Extracerebral Inhibitor of Dopamine Receptors, on Thyrotropin, Prolactin, Renin,Aldosterone, and 18-Hydroxycorticosterone Secretion in Man. Journal of Clinical Endocrinology and Metabolism, 1982, 54, 869-871.	3.6	54
77	Postprandial response of gastric slow waves: correlation of serosal recordings with the electrogastrogram. Digestive Diseases and Sciences, 2000, 45, 645-651.	2.3	54
78	Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis. Clinical Gastroenterology and Hepatology, 2019, 17, 1770-1779.e2.	4.4	53
79	Surgical Approaches to Treatment of Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, 151-167.	2.2	52
80	Small Intestinal Bacterial Overgrowth in Gastroparesis. Journal of Clinical Gastroenterology, 2010, 44, e8-e13.	2.2	51
81	Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 <i>vs</i> type 2 diabetes. Neurogastroenterology and Motility, 2016, 28, 1001-1015.	3.0	51
82	Median arcuate ligament syndrome: a possible cause of idiopathic gastroparesis. American Journal of Gastroenterology, 1997, 92, 519-23.	0.4	50
83	Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease. Digestive Diseases and Sciences, 1991, 36, 1556-1561.	2.3	49
84	Comparison of effects of nifedipine, propantheline bromide, and the combination on esophageal motor function in normal volunteers. Digestive Diseases and Sciences, 1984, 29, 300-304.	2.3	48
85	Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. Journal of Nuclear Medicine, 2018, 59, 691-697.	5.0	48
86	Gastric Neuromodulation With Enterra System for Nausea and Vomiting in Patients With Gastroparesis. Neuromodulation, 2012, 15, 224-231.	0.8	47
87	Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. American Journal of Gastroenterology, 2019, 114, 1886-1893.	0.4	45
88	Autonomic nerve function in adult patients with cyclic vomiting syndrome. Neurogastroenterology and Motility, 2011, 23, 439-443.	3.0	44
89	Cardiovascular Safety Profile and Clinical Experience With High-Dose Domperidone Therapy for Nausea and Vomiting. American Journal of the Medical Sciences, 2015, 349, 421-424.	1.1	44
90	Ethnic, Racial, and Sex Differences in Etiology, Symptoms,ÂTreatment, and Symptom Outcomes of Patients With Gastroparesis. Clinical Gastroenterology and Hepatology, 2019, 17, 1489-1499.e8.	4.4	43

#	Article	IF	CITATIONS
91	Neurochemical mechanisms and pharmacologic strategies in managing nausea and vomiting related to cyclic vomiting syndrome and other gastrointestinal disorders. European Journal of Pharmacology, 2014, 722, 79-94.	3.5	42
92	Prevalence of impaired gastric emptying of solids in systemic sclerosis: Diagnostic and therapeutic implications. Translational Research, 1998, 132, 541-546.	2.3	41
93	Evaluation of Five Probiotic Products for Label Claims by DNA Extraction and Polymerase Chain Reaction Analysis. Digestive Diseases and Sciences, 2005, 50, 1113-1117.	2.3	40
94	Who are the nonresponders to standard treatment with tricyclic antidepressant agents for cyclic vomiting syndrome in adults?. Alimentary Pharmacology and Therapeutics, 2010, 31, 295-301.	3.7	40
95	Disturbances of Esophageal Motility in Eosinophilic Esophagitis: A Case Series. Dysphagia, 2010, 25, 231-237.	1.8	40
96	Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 1991, 258, 136-42.	2.5	38
97	Gastroparesis, Pseudoachalasia and Impaired Intestinal Motility as Paraneoplastic Manifestations of Small Cell Lung Cancer. American Journal of the Medical Sciences, 2009, 338, 69-71.	1.1	37
98	Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: Relationship with etiology, gastric emptying, and symptom severity. Neurogastroenterology and Motility, 2020, 32, e13810.	3.0	37
99	Efficiency and efficacy of multiâ€channel gastric electrical stimulation. Neurogastroenterology and Motility, 2005, 17, 878-882.	3.0	36
100	Two hannel gastric pacing in patients with diabetic gastroparesis. Neurogastroenterology and Motility, 2011, 23, 912.	3.0	36
101	Is Interstitial Cells of Cajal‒opathy Present in Gastroparesis?. Journal of Neurogastroenterology and Motility, 2015, 21, 486-493.	2.4	36
102	Effectiveness of gastric electrical stimulation in gastroparesis: Results from a large prospectively collected database of national gastroparesis registries. Neurogastroenterology and Motility, 2019, 31, e13714.	3.0	36
103	What Role Do Salivary Inorganic Components Play in Health and Disease of the Esophageal Mucosa?. Digestion, 1995, 56, 24-31.	2.3	35
104	Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Alimentary Pharmacology and Therapeutics, 1998, 12, 167-174.	3.7	35
105	Frequency of Jackhammer Esophagus as the Extreme Phenotypes of Esophageal Hypercontractility Based on the New Chicago Classification. Journal of Clinical Gastroenterology, 2016, 50, 615-618.	2.2	35
106	Delayed Gastric Emptying Associates With Diabetic Complications in Diabetic Patients With Symptoms of Gastroparesis. American Journal of Gastroenterology, 2019, 114, 1778-1794.	0.4	34
107	Pathological Findings of the Antral and Pyloric Smooth Muscle in Patients with Gastroparesis-Like Syndrome Compared to Gastroparesis: Similarities and Differences. Digestive Diseases and Sciences, 2017, 62, 2828-2833.	2.3	33
108	Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. PLoS ONE, 2018, 13, e0194759.	2.5	33

#	Article	IF	CITATIONS
109	Central and Peripheral Effects of Transcutaneous Acupuncture Treatment for Nausea in Patients with Diabetic Gastroparesis. Journal of Neurogastroenterology and Motility, 2017, 23, 245-253.	2.4	31
110	Effect of nifedipine on gastric emptying in normal subjects. Digestive Diseases and Sciences, 1985, 30, 710-712.	2.3	29
111	Gastric dysmotility and gastroparesis. Current Treatment Options in Gastroenterology, 2001, 4, 179-191.	0.8	29
112	Endoscopic Pyloric Injection of Botulinum Toxin-A for the Treatment of Postvagotomy Gastroparesis. American Journal of the Medical Sciences, 2009, 337, 161-164.	1.1	29
113	Gastroparesis and the current use of prokinetic drugs. The Gastroenterologist, 1993, 1, 107-14.	0.6	29
114	Two-channel gastric pacing with a novel implantable gastric pacemaker accelerates glucagon-induced delayed gastric emptying in dogs. American Journal of Surgery, 2008, 195, 122-129.	1.8	28
115	The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis. Alimentary Pharmacology and Therapeutics, 1997, 11, 381-385.	3.7	27
116	Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation. American Journal of the Medical Sciences, 2016, 352, 231-238.	1.1	27
117	Diabetic gastroparesis: current challenges and future prospects. Clinical and Experimental Gastroenterology, 2018, Volume 11, 347-363.	2.3	27
118	Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. Alimentary Pharmacology and Therapeutics, 2020, 51, 1139-1148.	3.7	26
119	Gastrointestinal symptoms and the severity of COVIDâ€19: Disorders of gut–brain interaction are an outcome. Neurogastroenterology and Motility, 2022, 34, e14368.	3.0	26
120	Pharmacotherapy of gastroparesis. Expert Opinion on Pharmacotherapy, 2009, 10, 469-484.	1.8	25
121	Epidemiology and mechanisms of gastroesophageal reflux disease in the elderly: a perspective. Annals of the New York Academy of Sciences, 2016, 1380, 230-234.	3.8	25
122	Proteomics in gastroparesis: unique and overlapping protein signatures in diabetic and idiopathic gastroparesis. American Journal of Physiology - Renal Physiology, 2019, 317, G716-G726.	3.4	25
123	Effect of sucralfate and an aluminum hydroxide gel on gastric emptying of solids and liquids. Clinical Pharmacology and Therapeutics, 1985, 37, 629-632.	4.7	24
124	Primary Oesophageal Motility Disorders Current Therapeutic Concepts. Drugs, 1985, 30, 66-77.	10.9	24
125	Gender and Estradiol as Major Factors in the Expression and Dimerization of nNOSα in Rats with Experimental Diabetic Gastroparesis. Digestive Diseases and Sciences, 2012, 57, 2814-2825.	2.3	24
126	Correlation of Plasma Levels of Nifedipine and Cardiovascular Effects After Sublingual Dosing in Normal Subjects. Journal of Clinical Pharmacology, 1985, 25, 125-129.	2.0	23

#	Article	IF	CITATIONS
127	Cyclic vomiting syndrome: treatment options. Experimental Brain Research, 2014, 232, 2549-2552.	1.5	23
128	EUS-guided FNA biopsy of the muscularis propria of the antrum in patients with gastroparesis is feasible and safe. Gastrointestinal Endoscopy, 2016, 83, 327-333.	1.0	23
129	Constipation in Patients With Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit. Clinical Gastroenterology and Hepatology, 2022, 20, 546-558.e5.	4.4	23
130	Comparison of esophageal manometric characteristics in asymptomatic subjects and symptomatic patients with high-amplitude esophageal peristaltic contractions. American Journal of Gastroenterology, 1987, 82, 831-5.	0.4	23
131	Treatment of Refractory Gastroparesis: Gastric and Jejunal Tubes, Botox, Gastric Electrical Stimulation, and Surgery. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, 73-82.	1.4	22
132	Cannabinoid Hyperemesis Syndrome: Definition, Pathophysiology, Clinical Spectrum, Insights into Acute and Long-Term Management. Journal of Investigative Medicine, 2020, 68, 1309-1316.	1.6	22
133	Does a glucoseâ€based hydrogen and methane breath test detect bacterial overgrowth in the jejunum?. Neurogastroenterology and Motility, 2018, 30, e13350.	3.0	21
134	Spectrum of Gastrointestinal Manifestations in Joint Hypermobility Syndromes. American Journal of the Medical Sciences, 2018, 355, 573-580.	1.1	21
135	Gastroduodenal Injury: Role of Protective Factors. Current Gastroenterology Reports, 2019, 21, 34.	2.5	21
136	Motility Agents and the Gastrointestinal Tract. American Journal of the Medical Sciences, 1996, 312, 19-26.	1.1	20
137	Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology, 1983, 84, 1573-7.	1.3	20
138	Effects of ranitidine and of cimetidine on pentagastrin-stimulated gastric acid secretion. Clinical Pharmacology and Therapeutics, 1984, 35, 203-207.	4.7	19
139	Efficacy of Gastric Electrical Stimulation in Improving Functional Vomiting in Patients with Normal Gastric Emptying. Digestive Diseases and Sciences, 2010, 55, 983-987.	2.3	18
140	Does Grading the Severity of Gastroparesis Based on Scintigraphic Gastric Emptying Predict the Treatment Outcome of Patients with Gastroparesis?. Digestive Diseases and Sciences, 2011, 56, 1147-1153.	2.3	18
141	Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit. Digestive Diseases and Sciences, 2020, 65, 2311-2320.	2.3	18
142	Gender-Related Differences in Gastroparesis. American Journal of the Medical Sciences, 2020, 360, 474-483.	1.1	18
143	Rapid or Normal Gastric Emptying as New Supportive Criteria for Diagnosing Cyclic Vomiting Syndrome in Adults. Medical Science Monitor, 2014, 20, 1491-1495.	1.1	18
144	Mechanisms of High-Frequency Electrical Stimulation of the Stomach in Gastroparetic Patients. , 2006, 2006, 5400-3.		17

9

#	Article	IF	CITATIONS
145	Association of Marijuana Use and Cyclic Vomiting Syndrome. Pharmaceuticals, 2012, 5, 719-726.	3.8	17
146	Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. Annals of the New York Academy of Sciences, 2013, 1300, 278-295.	3.8	17
147	Outcomes of Treating Rumination Syndrome with a Tricyclic Antidepressant and Diaphragmatic Breathing. American Journal of the Medical Sciences, 2020, 360, 42-49.	1.1	17
148	A new nausea model in humans produces mild nausea without electrogastrogram and vasopressin changes. Neurogastroenterology and Motility, 1997, 9, 257-263.	3.0	16
149	Prokinetics in Diabetic Gastroparesis. Current Gastroenterology Reports, 2012, 14, 297-305.	2.5	16
150	Video Capsule Endoscopy: A Tool for the Assessment of Small Bowel Transit Time. Frontiers in Medicine, 2016, 3, 6.	2.6	16
151	Factors that contribute to the impairment of quality of life in gastroparesis. Neurogastroenterology and Motility, 2021, 33, e14087.	3.0	16
152	Diabetic and nondiabetic gastroparesis. Current Treatment Options in Gastroenterology, 1998, 1, 1-7.	0.8	15
153	Methodologic considerations for studies of chronic nausea and vomiting in adults and children. Autonomic Neuroscience: Basic and Clinical, 2017, 202, 28-39.	2.8	15
154	Delivery of Mesenchymal Stem Cells from Gelatin–Alginate Hydrogels to Stomach Lumen for Treatment of Gastroparesis. Bioengineering, 2018, 5, 12.	3.5	15
155	Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer. PLoS ONE, 2020, 15, e0238262.	2.5	15
156	Segmental high amplitude peristaltic contractions in the distal esophagus. American Journal of Gastroenterology, 1989, 84, 619-23.	0.4	15
157	Progress in Gastroparesis - A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium. Clinical Gastroenterology and Hepatology, 2022, 20, 2684-2695.e3.	4.4	15
158	Effect of fat preload on gastric myoelectrical activity in normal humans. Neurogastroenterology and Motility, 1993, 5, 281-287.	3.0	14
159	Pseudocholinesterase Deficiency: What the Proceduralist Needs to Know. American Journal of the Medical Sciences, 2019, 357, 263-267.	1.1	14
160	Central Nervous System Mechanisms of Nausea in Gastroparesis: An fMRI-Based Case–Control Study. Digestive Diseases and Sciences, 2020, 65, 551-556.	2.3	14
161	"Segmental aperistalsis" of the esophagus: a cause of chest pain and dysphagia. American Journal of Gastroenterology, 1988, 83, 1381-5.	0.4	14
162	Influence of Gastric Emptying and Gut Transit Testing on Clinical Management Decisions in Suspected Gastroparesis. Clinical and Translational Gastroenterology, 2019, 10, e00084.	2.5	13

#	Article	IF	CITATIONS
163	Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. Clinical Gastroenterology and Hepatology, 2022, 20, e452-e464.	4.4	13
164	ls symptom relief associated with reduction in gastric retention after gastric electrical stimulation treatment in patients with gastroparesis? A sensitivity analysis with logistic regression models. Neurogastroenterology and Motility, 2012, 24, 639.	3.0	12
165	Clinical Manifestation and Natural History of Gastroparesis. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 27-38.	1.4	12
166	Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity. Neurogastroenterology and Motility, 2020, 32, e13720.	3.0	12
167	Small Bowel Dysmotility, Pseudoobstruction, and Functional Correlation with Histopathology: Lessons Learned. Current Gastroenterology Reports, 2020, 22, 14.	2.5	12
168	Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer. Anticancer Research, 2020, 40, 857-864.	1.1	12
169	Esophageal perforation post pneumatic dilatation for achalasia managed by esophageal stenting. American Journal of Case Reports, 2013, 14, 532-535.	0.8	12
170	Body weight in patients with idiopathic gastroparesis. Neurogastroenterology and Motility, 2021, 33, e13974.	3.0	12
171	Efficacy of needleless transcutaneous electroacupuncture in synchronization with breathing for symptomatic idiopathic gastroparesis: A blinded and controlled acute treatment trial. Neurogastroenterology and Motility, 2018, 30, e13361.	3.0	11
172	Investigation of Oral, Gastric, and Duodenal Microbiota in Patients with Upper Gastrointestinal Symptoms. Journal of Investigative Medicine, 2021, 69, 870-877.	1.6	11
173	Elevated Serum Ghrelin Levels in Adult Patients With Cyclic Vomiting Syndrome. American Journal of Gastroenterology, 2011, 106, 1858-1859.	0.4	10
174	Is 'ICC-opathy' present in gastroparesis-like syndrome?. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 375-376.	17.8	10
175	Increased Expression of Pyloric ERÎ ² Is Associated With Diabetic Gastroparesis in Streptozotocin-Induced Male Diabetic Rats. Gastroenterology Research, 2016, 9, 39-46.	1.3	9
176	Interpreting the Lactulose Breath Test for the Diagnosis of Small Intestinal Bacterial Overgrowth. American Journal of the Medical Sciences, 2016, 351, 229-232.	1.1	9
177	Multicenter, Double-Blind, Placebo-Controlled Crossover Study to Assess the Acute Prokinetic Efficacy of Nizatidine-Controlled Release (150 and 300mg) in Patients With Gastroesophageal Reflux Disease. American Journal of the Medical Sciences, 2010, 340, 259-263.	1.1	8
178	Adverse Effects of Domperidone: Prolonged QuesT for Knowledge?. Digestive Diseases and Sciences, 2016, 61, 3384-3386.	2.3	8
179	The Prevalence of Biopsy-Proven Eosinophilic Esophagitis in Hispanics Undergoing Endoscopy Is Infrequent Compared to Caucasians: A Cross-Sectional Study. Digestive Diseases and Sciences, 2017, 62, 3511-3516.	2.3	8
180	Nonspecific motility disorders, irritable esophagus, and chest pain. Annals of the New York Academy of Sciences, 2013, 1300, 96-109.	3.8	7

#	Article	IF	CITATIONS
181	Relamorelin in Patients with Diabetic Gastroparesis: Efficacy and Safety Results from a Phase 2B Randomized, Double-Blind, Placebo-Controlled, 12-Week Study (RM-131-009). Gastroenterology, 2017, 152, S139-S140.	1.3	7
182	Cannabis for Gastroparesis: Hype or Hope?. American Journal of Gastroenterology, 2019, 114, 865-866.	0.4	7
183	Plasma endocannabinoids and cannabimimetic fatty acid derivatives are altered in gastroparesis: A sex― and subtypeâ€dependent observation. Neurogastroenterology and Motility, 2021, 33, e13961.	3.0	7
184	Evaluation of acotiamide for the treatment of functional dyspepsia. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1161-1168.	3.3	6
185	Safety of treatment for gastroparesis. Expert Opinion on Drug Safety, 2016, 15, 937-945.	2.4	6
186	Pseudoachalasia: Still a Tough Clinical Challenge. American Journal of Case Reports, 2015, 16, 768-773.	0.8	6
187	Medication-Induced Gastroparesis: A Case Report. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110519.	0.6	6
188	Effect of liquid and solid test meals on symptoms and gastric myoelectrical activity in patients with gastroparesis and functional dyspepsia. Neurogastroenterology and Motility, 2023, 35, e14376.	3.0	6
189	The Role of Hope in the Psychological Adjustment of Gastropareutic Patients Receiving the Gastric Pacemaker: A Longitudinal Study. Journal of Clinical Psychology in Medical Settings, 2006, 13, 46-53.	1.4	5
190	573 High Prevalence and Underdiagnosis of Gastroparesis Symptoms Among Patients With Type 1 and Type 2 Diabetes Mellitus. Gastroenterology, 2013, 144, S-107.	1.3	5
191	Acute Pancreatitis as the Initial Presentation of Systematic Lupus Erythematosus. Case Reports in Gastrointestinal Medicine, 2014, 2014, 1-4.	0.3	5
192	296 Effectiveness of Gastric Electrical Stimulation in Gastroparesis: Results From a Large Prospectively Collected Database of a National Gastroparesis Registry. Gastroenterology, 2015, 148, S-65.	1.3	5
193	143 - Gastric Emptying Changes over Time in Gastroparesis: Comparison of Initial and 48 Week Follow up Gastric Emptying Tests in the Gastroparesis Registry of the Gastroparesis Consortium. Gastroenterology, 2018, 154, S-39.	1.3	5
194	Baseline Predictors of Longitudinal Changes in Symptom Severity and Quality of Life in Patients With Suspected Gastroparesis. Clinical Gastroenterology and Hepatology, 2022, 20, e407-e428.	4.4	5
195	Median Arcuate Ligament Syndrome Clinical Presentation, Pathophysiology, and Management: Description of Four Cases. Gastrointestinal Disorders, 2021, 3, 44-50.	0.8	5
196	Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer. Frontiers in Oncology, 2021, 11, 772225.	2.8	5
197	Postprandial symptoms in patients with symptoms of gastroparesis: roles of gastric emptying and accommodation. American Journal of Physiology - Renal Physiology, 2022, 323, G44-G59.	3.4	5
198	Mo2074 Understanding the Etiologies, Clinical Spectrum and Diagnostic Challenge of Dumping Syndrome. Gastroenterology, 2013, 144, S-734.	1.3	4

#	Article	IF	CITATIONS
199	Cyclic vomiting syndrome: an overview for clinicians. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1137-1143.	3.0	4
200	Gastroparesis in chronic dyspepsia (CD) and in diabetics with dyspeptic symptoms (DD): Diagnostic sensitivity and specificity of gastric scintigraphy. Gastroenterology, 2001, 120, A22-A23.	1.3	3
201	Effectiveness of Bulking Agent (Solesta) Therapy in Fecal Incontinence in Patients Refractory to Conventional Therapies. American Journal of the Medical Sciences, 2017, 354, 476-479.	1.1	3
202	Current and future treatment management strategies for gastroparesis. Expert Opinion on Orphan Drugs, 2019, 7, 211-221.	0.8	3
203	Efficacy and Safety of Dor Fundoplication in Patients with Severe Gastroparesis and Refractory Gastroesophageal Reflux Disease. Gastrointestinal Disorders, 2020, 2, 134-139.	0.8	3
204	Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. Expert Review of Endocrinology and Metabolism, 2021, 16, 25-35.	2.4	3
205	Prevalence and clinical correlates of antinuclear antibody in patients with gastroparesis. Neurogastroenterology and Motility, 2022, 34, e14270.	3.0	3
206	Gastric Electrical Stimulation, Pyloroplasty, Gastrectomy, and Acustimulation for the Treatment of Nausea and Vomiting in the Setting of Gastroparesis. , 2017, , 139-151.		3
207	Subtotal Gastrectomy as "Last Resort―Consideration in the Management of Refractory Rumination Syndrome. Gastroenterology Research, 2014, 7, 98-101.	1.3	3
208	Decreased Level of Neuropeptide Y Is Associated With Gastroparesis in Male Diabetic Rats. Gastroenterology Research, 2020, 13, 246-252.	1.3	3
209	Su1455 Relationship of Gastric Emptying With Numbers of Interstitial Cells of Cajal in Antral Muscularis Propria of Gastroparesis Patient. Gastroenterology, 2015, 148, S-517.	1.3	2
210	Pneumatic Dilation of the Lower Esophageal Sphincter Can Now Be Successfully Performed Without Morbidity. American Journal of the Medical Sciences, 2016, 352, 443-447.	1.1	2
211	1082 Gastroparesis and Functional Dyspepsia of Postprandial Discomfort Phenotype Have Similar Clinical, Pathophysiological and Histopathological Features. Gastroenterology, 2016, 150, S215.	1.3	2
212	Per Oral Pyloromyotomy for Gastroparesis: A Systematic Review of the Current Literature and Future Recommendations. Gastrointestinal Disorders, 2020, 2, 415-422.	0.8	2
213	Alcohol and Gastric Motility: Pathophysiological and Therapeutic Implications. Journal of Investigative Medicine, 2020, 68, 965-971.	1.6	2
214	Pharmacologic modulation of motility. Yale Journal of Biology and Medicine, 1999, 72, 173-80.	0.2	2
215	Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms. Journal of Investigative Medicine, 2022, 70, 1225-1232.	1.6	2
216	Measurement of electrical activity of the human small intestine using surface electrodes. , 1992, , .		1

Measurement of electrical activity of the human small intestine using surface electrodes. , 1992, , . 216

#	Article	IF	CITATIONS
217	Postsurgical Gastroparesis. , 2012, , 191-203.		1
218	Su1444 Analysis of Interstitial Cells of Cajal in Pyloric Smooth Muscle in Gastroparesis Patients. Gastroenterology, 2015, 148, S-513.	1.3	1
219	Neurophysiology and new techniques to assess esophageal sensory function: an update. Annals of the New York Academy of Sciences, 2016, 1380, 78-90.	3.8	1
220	Comparison of the Status of Interstitial Cells of Cajal in the Smooth Muscle of the Antrum and Pylorus in Diabetic Male and Female Patients with Severe Gastroparesis. Gastrointestinal Disorders, 2020, 2, 236-245.	0.8	1
221	The pyloric revolution: Patient selection. , 2021, , 461-471.		1
222	Gastric Electrical Stimulation for Gastroparesis. , 2012, , 353-364.		1
223	Richard W. McCallum, MD: New Editor-in-Chief, Journal of Investigative Medicine. Journal of Investigative Medicine, 2020, 68, 1-2.	1.6	1
224	The End of the Beginning: a Transition to the "Brave New World― Journal of Investigative Medicine, 2021, 69, 1-1.	1.6	1
225	Another Sherlock Holmes Mystery: Abdominal Pain Explained by Median Arcuate Ligament Syndrome. Journal of Investigative Medicine High Impact Case Reports, 2022, 10, 232470962210849.	0.6	1
226	â€~Alkaline' gastro-esophageal reflux - A clinical entity?. Ecological Management and Restoration, 1994, 7, 73-79.	0.4	0
227	182 NO ASSOCIATION BETWEEN CHANGES IN SYMPTOMS AND GASTRIC EMPTYING IN GASTROPARETIC PATIENTS TREATED WITH GASTRIC ELECTRICAL STIMULATION.:. Journal of Investigative Medicine, 2006, 54, S288.4-S288.	1.6	0
228	Southern Society for Clinical Investigation Founders' Medal Acceptance. American Journal of the Medical Sciences, 2009, 338, 7-8.	1.1	0
229	Food Impaction Due to Nutcracker Esophagus. American Journal of the Medical Sciences, 2013, 346, 76-79.	1.1	0
230	Charles M. Mansbach, MD, 1937–2015. American Journal of the Medical Sciences, 2016, 351, 127-128.	1.1	0
231	Gastric Pacing. , 2018, , 283-292.		0
232	Endoscopic Approaches for Gastroparesis. , 2019, , 322-329.e2.		0
233	Gastroparesis in Older Adults. , 2019, , 1-16.		0
234	Dumping Syndrome. , 2020, , 73-81.		0

#	Article	IF	CITATIONS
235	Physician-scientist and the COVID-19 dilemma. Journal of Investigative Medicine, 2020, 68, 1205-1205.	1.6	Ο
236	Plummer-Vinson Syndrome: A Time for Redefinition and New Perspectives. Gastrointestinal Disorders, 2020, 2, 408-414.	0.8	0
237	Status of Brain Imaging in Gastroparesis. Gastrointestinal Disorders, 2020, 2, 58-70.	0.8	0
238	Surgical management of gastroparesis. , 2021, , 431-439.		0
239	Idiopathic gastroparesis. , 2021, , 265-281.		0
240	Gastroparesis in Older Adults. , 2021, , 1145-1159.		0
241	Gastric electrical stimulation for gastroparesis. , 2021, , 413-429.		Ο
242	Studies from the NIH Gastroparesis Clinical Research Consortium: Towards improving our understanding and treatment of gastroparesis. , 2021, , 443-449.		0
243	Abdominal pain in gastroparesis: Prevalence, potential causes and management. , 2021, , 361-375.		0
244	Cyclic Vomiting Syndrome (CVS). , 2021, , 1-7.		0
245	â€~Wisdom in the time of COVID-19'. Journal of Investigative Medicine, 2021, 69, 305-306.	1.6	0
246	Antiemetic therapy for gastroparesis. , 2021, , 341-359.		0
247	Update on Journal of Investigative Medicine—yes, we are on the right road!. Journal of Investigative Medicine, 2021, 69, 687-688.	1.6	0
248	Electrocardiogram Following the Implantation of a Pacing System. JACC: Clinical Electrophysiology, 2021, 7, 828-829.	3.2	0
249	Response to 'Fool's gold: diseased marijuana and cannabis hyperemesis syndrome'. Journal of Investigative Medicine, 2021, 69, 1065-1066.	1.6	Ο
250	Good news continues for JIM in 2021. Journal of Investigative Medicine, 2021, 69, 1263-1264.	1.6	0
251	Lateâ€onset rapid gastric emptying: Identification of a new abnormal finding in patients with otherwise normal results on gastric emptying scintigraphy. Neurogastroenterology and Motility, 2021, 33, e14219.	3.0	Ο
252	Natural history of patients with gastroparesis. , 2021, , 35-44.		0

Natural history of patients with gastroparesis. , 2021, , 35-44.

#	Article	IF	CITATIONS
253	Efficacy and Safety of Robotic Dor Fundoplication on Severe Gastroesophageal Reflux Disease in Patients With Scleroderma. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110512.	0.6	0
254	Gastroparesis in Older Adults. , 2012, , 301-309.		0
255	Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer. Immunotherapy, 2020, 12, 1293-1302.	2.0	0
256	Twenty-five years ago: a new journal is born in a changing world. Journal of Investigative Medicine, 2020, 68, 1125-1127.	1.6	0
257	Advances in the management of atrial fibrillation with a special focus on non-pharmacological approaches to prevent thromboembolism: a review of current recommendations. Journal of Investigative Medicine, 2020, 68, 1317-1333.	1.6	0
258	Dysphagia as the Presenting Symptom for Inclusion Body Myositis. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110502.	0.6	0
259	Banner year for the <i>Journal of Investigative Medicine</i> . Journal of Investigative Medicine, 2022, 70, 859-860.	1.6	0
260	Title is missing!. , 2020, 15, e0238262.		0
261	Title is missing!. , 2020, 15, e0238262.		0
262	Title is missing!. , 2020, 15, e0238262.		0
263	Title is missing!. , 2020, 15, e0238262.		0
264	Title is missing!. , 2020, 15, e0238262.		0
265	Title is missing!. , 2020, 15, e0238262.		0